Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 26, Issue 13, 2008, Pages 2224-2226

  Chu, Edward ^a   Cartwright, Thomas H ^b  

^a YALE CANCER CENTER   (United States)

^b Ocala Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG COST; DRUG SAFETY; HEALTH CARE COST; HUMAN; LETTER; METASTASIS; PRIORITY JOURNAL; VALIDITY; COLORECTAL TUMOR; ECONOMICS; HOSPITAL COST; METHODOLOGY; NOTE; PATHOLOGY; PATIENT SELECTION; PHARMACOECONOMICS; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FLUOROURACIL; HOSPITAL COSTS; HUMANS; MODELS, ECONOMIC; NEOPLASM METASTASIS; PATIENT SELECTION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 43749118692     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.2826     Document Type: Letter

References (7)

1. Mayer RJ: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 25:4165-4167, 2007
2. Cassidy J, Clarke S, Diaz-Rubio E, et al: XELOX vs. FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase II trial in first-line metastatic colorectal cancer (MCRC). J Clin Oncol 25:171s, 2007 (suppl; abstr 4030)
3. Ducreux M, Bennouna J, Hebbar M, et al: Efficacy and safety findings from a randomized phase II study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 25:170s, 2007 (suppl; abstr 4029)
4. Garrison L, Cassidy J, Saleh M, et al: Cost comparison of XELOX compared to FOLFOX-4 with or without bevacizumab (bev) in metastatic colorectal cancer. J Clin Oncol 25:182s, 2007 (suppl; abstr 4074)
5. Scheithauer W, Cassidy J, Figer A, et al: A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX-4 bevacizumab (A). J Clin Oncol 25:188s, 2007 (suppl; abstr 4098)
6. Perrocheau G, Bennouna J, Ducreux M, et al: Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting. J Clin Oncol 25:184s, 2007 (suppl; abstr 4083)
7. Chu E, Zelt S, Song X: A claims database cost-comparison analysis of capecitabine in the treatment of patients with colon or rectal cancer (CRC). Gastrointestinal Cancer Symposium, January 26-28, 2008 (abstr 364)